Effectiveness of double-dose dolutegravir in people receiving rifampin-based tuberculosis treatment: an observational, cohort study of people with HIV from six countries.
N Sarita ShahCissy KityoMichael D HughesCaitlyn McCarthyCarole WallisMina HosseinipourDeborah LangatMulinda NyirendaMohammed RassoolRodney DawsonYvetot JosephFatma SomeRosie MngqbisaPamela Grace MukwekwerereElizabeth WoolleyCatherine GodfreyYukari C ManabeJohn W MellorsCharles FlexnerGary Maartensnull nullPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)
In routine programmatic settings, concurrent rifampin-containing TB treatment and TLD + 50 was feasible, well-tolerated, and achieved high rates of viral suppression in a cohort of predominantly ART-naïve people with TB/HIV.
Keyphrases
- antiretroviral therapy
- hiv infected
- mycobacterium tuberculosis
- human immunodeficiency virus
- hiv aids
- hiv positive
- hepatitis c virus
- systematic review
- randomized controlled trial
- emergency department
- squamous cell carcinoma
- combination therapy
- clinical practice
- radiation therapy
- pulmonary tuberculosis
- rectal cancer